Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use.

TitleGender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use.
Publication TypeJournal Article
Year of Publication2012
AuthorsHeinzerling, KG, Shoptaw S
JournalGender medicine
Volume9
Issue2
Pagination112-20
Date Published2012 Apr
ISSN1878-7398
Abstract

Frequency of pretreatment methamphetamine (MA) use is an important predictor of outcomes of treatment for MA dependence. Preclinical studies suggest females self-administer more MA than males, but few clinical studies have examined potential sex differences in the frequency of MA use. Estrogen increases expression of brain-derived neurotrophic factor (BDNF), which has effects on MA-induced striatal dopamine release and protects against MA-induced neurotoxicity.

DOI10.1111/j.1465-3362.2012.00423.x
Alternate JournalGend Med